Study of RO6807952 in Patients With Diabetes Mellitus Type 2

NCT01516476 on ClinicalTrials.gov · last registry update 2016-11-02

Stopped early, having planned 2 participants. The sponsor logged completion for January 2012. Primary outcome, as filed: Change in hemoglobin A1c (HA1c). liraglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: TERMINATED
Phase: P2
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: Hoffmann-La Roche
Sponsor type: Industry
Enrollment: 2
Started: 2011-11
Primary completion: 2012-01 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in hemoglobin A1c (HA1c)

Conditions studied

Diabetes Mellitus Type 2

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.